- Home
- RIGL vs FOF Comparison
RIGL vs FOF Comparison
Compare RIGL & FOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- FOF
- Stock Information
- Founded
- RIGL 1996
- FOF 2006
- Country
- RIGL United States
- FOF United States
- Employees
- RIGL N/A
- FOF N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- FOF Investment Managers
- Sector
- RIGL Health Care
- FOF Finance
- Exchange
- RIGL Nasdaq
- FOF Nasdaq
- Market Cap
- RIGL 335.5M
- FOF 354.8M
- IPO Year
- RIGL 2000
- FOF N/A
- Fundamental
- Price
- RIGL $38.85
- FOF $13.04
- Analyst Decision
- RIGL Buy
- FOF
- Analyst Count
- RIGL 5
- FOF 0
- Target Price
- RIGL $38.20
- FOF N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- FOF 58.7K
- Earning Date
- RIGL 08-05-2025
- FOF 01-01-0001
- Dividend Yield
- RIGL N/A
- FOF 9.07%
- EPS Growth
- RIGL N/A
- FOF N/A
- EPS
- RIGL 5.43
- FOF N/A
- Revenue
- RIGL $267,921,000.00
- FOF N/A
- Revenue This Year
- RIGL $59.93
- FOF N/A
- Revenue Next Year
- RIGL N/A
- FOF N/A
- P/E Ratio
- RIGL $7.15
- FOF N/A
- Revenue Growth
- RIGL 105.62
- FOF N/A
- 52 Week Low
- RIGL $12.66
- FOF $9.59
- 52 Week High
- RIGL $43.72
- FOF $11.75
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- FOF 58.11
- Support Level
- RIGL $39.00
- FOF $13.01
- Resistance Level
- RIGL $42.08
- FOF $13.13
- Average True Range (ATR)
- RIGL 2.32
- FOF 0.09
- MACD
- RIGL -0.37
- FOF -0.01
- Stochastic Oscillator
- RIGL 53.26
- FOF 59.05
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.